16.16
1.48%
+0.235
Dopo l'orario di chiusura:
15.83
-0.33
-2.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Harrow Inc Borsa (HROW) Ultime notizie
B. Riley Research Analysts Lower Earnings Estimates for Harrow, Inc. (NASDAQ:HROW) - MarketBeat
MarketBeat
Harrow Inc [HROW] stock for 199400 USD was bought by Opaleye Management Inc. – Knox Daily - Knox Daily
Knox Daily
Craig Hallum Increases Harrow (NASDAQ:HROW) Price Target to $26.00 - MarketBeat
MarketBeat
Harrow (NASDAQ:HROW) Rating Reiterated by B. Riley - MarketBeat
MarketBeat
Harrow, Inc. (NASDAQ:HROW) to Post Q4 2024 Earnings of $0.17 Per Share, B. Riley Forecasts - MarketBeat
MarketBeat
The growth track for Harrow Inc (HROW) has changed recently – Sete News - SETE News
SETE News
Harrow to Present at Two Investor Conferences in May - Business Wire
Business Wire
Earnings call: Harrow Inc. reports robust revenue growth in Q1 2024 - Investing.com
Investing.com
Harrow (NASDAQ:HROW) Shares Gap Up to $12.07 - MarketBeat
MarketBeat
Harrow Market 2023-2030 Insight View with Size and Regional Analysis | Survey Report by Absolute Reports - News Channel Nebraska
News Channel Nebraska
Examining Harrow Inc (HROW) stock is warranted – US Post News - US Post News
US Post News
Harrow: Q1 Earnings Snapshot | Tennessee News - Crossville Chronicle
Crossville Chronicle
Harrow Announces First Quarter 2024 Financial Results - Yahoo Finance
Yahoo Finance
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial - Business Wire
Business Wire
Harrow: Q1 Earnings Snapshot - Houston Chronicle
Houston Chronicle
Harrow Borough FC part company with manager and three coaches - Harrow Online
Harrow Online
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for ... - The Globe and Mail
The Globe and Mail
Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Movies Canada
Yahoo Movies Canada
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom (NASDAQ:HROW) - Seeking Alpha
Seeking Alpha
Around $2M Bet On This Industrial Stock? Check Out These 3 Stocks Insiders Are Buying - Harrow (NASDAQ:HR - Benzinga
Benzinga
Opaleye management buys $204k of Harrow Inc. stock - Investing.com
Investing.com
Insider Buying: Harrow, Inc. (NASDAQ:HROW) Major Shareholder Buys 11,715 Shares of Stock - MarketBeat
MarketBeat
Over $24M Bet On RXO? Check Out These 3 Stocks Insiders Are Buying - Harrow (NASDAQ:HROW), RXO (NYSE:RXO) - Benzinga
Benzinga
Drug company defends 486% price increase for eye treatment - STAT
STAT
Melt Pharmaceuticals raises $24 million for drug development - Nashville Business Journal - The Business Journals
The Business Journals
Opaleye Management Inc. buys $641k of Harrow Inc. common stock - Investing.com
Investing.com
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Benzinga
Insiders Buying Greenwich LifeSciences And 2 Other Stocks - Markets Insider
Markets Insider
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Benzinga
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga
Why Is Harrow (HROW) Stock Down 7% Today? - InvestorPlace
InvestorPlace
Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023 - GuruFocus.com
GuruFocus.com
Harrow: Q4 Earnings Snapshot - Quartz
Quartz
Disgraced Harrow company director convicted of falsifying medicine quality data - Harrow Online
Harrow Online
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products - Vision Monday
Vision Monday
Harrow's Drug Iheezo Is Off To A Great Start (NASDAQ:HROW) - Seeking Alpha
Seeking Alpha
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products - Business Wire
Business Wire
Harrow Announces New Appointments to Board of Directors - Vision Monday
Vision Monday
Harrow Announces New Appointments to its Board of Directors - Business Wire
Business Wire
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine ... - Business Wire
Business Wire
Vevye Partners with PhilRx, Apollo Care, and PARx Solutions to Enhance Patient Access to Innovative Dry Eye Treatment - Medriva
Medriva
Melt Pharmaceuticals Provides Corporate Update - Yahoo Finance
Yahoo Finance
Harrow Completes Transfer of the TRIESENCE® New Drug Application - Yahoo Finance
Yahoo Finance
Harrow to Present at Two Investor Conferences in November - Business Wire
Business Wire
Opaleye Management Inc. Bolsters Position in Harrow Inc. with Recent Acquisition - Yahoo Finance
Yahoo Finance
Despite Q3 Earnings Miss, Harrow Is Still Appealing For 2024 (NASDAQ:HROW) - Seeking Alpha
Seeking Alpha
HROW Stock Quote Price and Forecast - CNN
CNN
Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript - Yahoo Finance
Yahoo Finance
Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023 - Yahoo Finance
Yahoo Finance
Capitalizzazione:
|
Volume (24 ore):